Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Reynes

Showing results (151-160 of 200) with videos related to

Pageof 20
Sort By:
Lancet (London, England)|September 5, 2017
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialPaul E Sax, Anton Pozniak, M Luisa Montes, et al.
Frontiers in Immunology|April 16, 2021
Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral TherapyMehwish Younas, Christina Psomas, Christelle Reynes, et al.
Pharmacotherapy|March 1, 2019
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL StudyMinh Patrick Lê, Marc-Antoine Valantin, Lambert Assoumou, et al.
The Journal of Infectious Diseases|June 2, 2011
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trialOdile Launay, Corinne Desaint, Christine Durier, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2019
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL studyChristine Katlama, Lambert Assoumou, Marc-Antoine Valantin, et al.
The Journal of Infection|June 6, 2017
Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?Pierre Pradat, Pascal Pugliese, Isabelle Poizot-Martin, et al.
AIDS (London, England)|February 14, 2018
Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIVPierre Pradat, Thomas Huleux, François Raffi, et al.
Ebiomedicine|July 19, 2016
One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH studyChristina Psomas, Mehwish Younas, Christelle Reynes, et al.
BMC Medicine|December 19, 2017
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to eliminationVictor Virlogeux, Fabien Zoulim, Pascal Pugliese, et al.
Peer Community Journal|March 18, 2025
Factors shaping vaginal microbiota long-term community dynamics in young adult womenTsukushi Kamiya, Nicolas Tessandier, Baptiste Elie, et al.
Pageof 20

Showing results (151-160 of 200) with videos related to

Sort By:
Pageof 20
Lancet (London, England)|September 5, 2017
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialPaul E Sax, Anton Pozniak, M Luisa Montes, et al.
Frontiers in Immunology|April 16, 2021
Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral TherapyMehwish Younas, Christina Psomas, Christelle Reynes, et al.
Pharmacotherapy|March 1, 2019
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL StudyMinh Patrick Lê, Marc-Antoine Valantin, Lambert Assoumou, et al.
The Journal of Infectious Diseases|June 2, 2011
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trialOdile Launay, Corinne Desaint, Christine Durier, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2019
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL studyChristine Katlama, Lambert Assoumou, Marc-Antoine Valantin, et al.
The Journal of Infection|June 6, 2017
Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?Pierre Pradat, Pascal Pugliese, Isabelle Poizot-Martin, et al.
AIDS (London, England)|February 14, 2018
Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIVPierre Pradat, Thomas Huleux, François Raffi, et al.
Ebiomedicine|July 19, 2016
One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH studyChristina Psomas, Mehwish Younas, Christelle Reynes, et al.
BMC Medicine|December 19, 2017
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to eliminationVictor Virlogeux, Fabien Zoulim, Pascal Pugliese, et al.
Peer Community Journal|March 18, 2025
Factors shaping vaginal microbiota long-term community dynamics in young adult womenTsukushi Kamiya, Nicolas Tessandier, Baptiste Elie, et al.
Pageof 20